Clinical pharmacology of moxalactam in patients with malignant disease.
Pharmacological studies of moxalactam were conducted with 37 cancer patients. Intramuscular administration of 500 mg of moxalactam to 10 patients produced a mean peak serum concentration of 12.4 micrograms/ml. The serum terminal-phase half-life was 3.9 h. Intravenous administration of 500 mg of moxa...
Gardado en:
| Publicado en: | Antimicrob Agents Chemother |
|---|---|
| Principais autores: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
American Society for Microbiology (ASM)
1981
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC181493/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/6454389/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.19.4.639 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|